Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.58 |
| ▸ | BRD2 | P25440 | 7/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902486 | 0.88 | BRD4 (0.55) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL11980665 | 0.88 | BRD4 (0.46) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18250005 | 0.84 | BRD4 (0.44) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249906 | 0.83 | BRD4 (0.43) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18716011 | 0.82 | BRD4 (0.59) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL15801132 | 0.82 | BRD4 (0.56) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL15985177 | 0.82 | BRD4 (0.68) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1903177 | 0.81 | BRD4 (0.67) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1903791 | 0.81 | BRD4 (0.51) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL14756281 | 0.79 | CYP3A4 (0.75) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699573-B1 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2699573-B1 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2015081280-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2015-05-14 | — | — | US | disclosed |
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2015-05-14 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012143416-A2 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| EP-2496576-A1 | IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496235-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011054843-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054843-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885CYP3A4 4765/4885CYP2C9 4863/4885 |
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885CYP3A4 4765/4885CYP2C9 4863/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885CYP3A4 4738/4885CYP2C9 4863/4885 |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885CYP3A4 1579/4885CYP2C9 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.